Phaseline

Companies › Rigel Pharmaceuticals

Rigel Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 13 registered trials: 7 Phase 2, 4 Phase 1, 2 Phase 4; Oncology, Other, Hematology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Olutasidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 4AML (Acute Myeloid Leukemia); High Grade Glioma; Targeted Therapy; Myelodysplastic Syndromes …Apr 2027
Pralsetinib
Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
RET, CCDC6, KIF5BPhase 4NSCLC (Non-small Cell Lung Cancer)Jul 2027
R906289 Monosodium (R289 Na)–Phase 1Low Risk Myelodysplastic SyndromesDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07411586OlutasidenibPhase 1Acute Myeloid LeukemiaOncologyJan 2027
NCT06543381OlutasidenibPhase 1Acute Myeloid LeukemiaOncologyFeb 2027
NCT07486713OlutasidenibPhase 4AML (Acute Myeloid Leukemia)OncologyApr 2027
NCT07032727OlutasidenibPhase 2Targeted TherapyOncologyJun 2027
NCT06445959OlutasidenibPhase 1Mutant IDH1 Inhibitor OlutasidenibOtherJun 2027
NCT07704658PralsetinibPhase 4NSCLC (Non-small Cell Lung Cancer)OncologyJul 2027
NCT06566742OlutasidenibPhase 2Myelodysplastic SyndromesOncologyAug 2027
NCT07304011OlutasidenibPhase 2Acute Myeloid LeukemiaOncologyDec 2027
NCT05308264R906289 Monosodium (R289 Na)Phase 1Low Risk Myelodysplastic SyndromesHematologyDec 2027
NCT06668584OlutasidenibPhase 2Myeloid MalignanciesOncologyDec 2027
NCT07471841OlutasidenibPhase 2IDH1 MutationOncologyJun 2028
NCT06782542OlutasidenibPhase 2Acute Myeloid LeukemiaOncologyMar 2029
NCT06161974OlutasidenibPhase 2High Grade GliomaOncologyJun 2029

From the company's SEC filings

Cash and short-term investments of $99m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IDH1 (1) RET (1) CCDC6 (1) KIF5B (1)

Companies with the same targets

Eli Lilly Roche Servier Chia Tai Tianqing Pharmaceutical Group Nuvation Bio Bristol-Myers Squibb Kissei Pharmaceutical Servier Affaires Médicales Hutchmed Servier Bio-Innovation

Companies built like this

Nuvation Bio Nurix Therapeutics Compass Therapeutics Dizal Pharmaceuticals Shanghai Kechow Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.